Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Notes Payables (2021 - 2025)

Ascendis Pharma A (ASND) has disclosed Notes Payables for 5 consecutive years, with $499.8 million as the latest value for Q4 2025.

  • Quarterly Notes Payables rose 2.08% to $499.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $499.8 million through Dec 2025, up 2.08% year-over-year, with the annual reading at $499.8 million for FY2025, 2.08% up from the prior year.
  • Notes Payables hit $499.8 million in Q4 2025 for Ascendis Pharma A, up from $489.6 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $499.8 million in Q4 2025 to a low of $8.0 million in Q4 2021.
  • Historically, Notes Payables has averaged $289.5 million across 5 years, with a median of $438.0 million in 2023.
  • Biggest five-year swings in Notes Payables: soared 3591.46% in 2023 and later grew 2.08% in 2025.
  • Year by year, Notes Payables stood at $8.0 million in 2021, then skyrocketed by 48.28% to $11.9 million in 2022, then skyrocketed by 3591.46% to $438.0 million in 2023, then increased by 11.79% to $489.6 million in 2024, then grew by 2.08% to $499.8 million in 2025.
  • Business Quant data shows Notes Payables for ASND at $499.8 million in Q4 2025, $489.6 million in Q4 2024, and $438.0 million in Q4 2023.